Optimizing targeted gene delivery: Chemical modification of viral vectors and synthesis of artificial virus vector systems

被引:55
作者
Boeckle, Sabine [1 ]
Wagner, Ernst [1 ]
机构
[1] Univ Munich, Dept Pharm, D-81377 Munich, Germany
关键词
gene transfer; nonviral vector; receptor targeting; synthetic virus; viral vector;
D O I
10.1208/aapsj080483
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
In comparison to classical medicines, gene therapy has the potential to mediate the highest possible level of therapeutic specificity. Every normal or diseased cell can switch on or off a gene expression cassette in a tissue-, disease-, and time-dependent fashion, by use of specific transcription factors that are active only in a given unique situation. In practice, we face the problem in realizing the concept: the delivery of nucleic acids into target cells is very ineffective and presents a formidable challenge. Key issues for future developments include improved targeting, enhanced intracellular uptake, and reduced toxicity of gene vectors. The currently used classes of vectors have complementary characteristics, such as high intracellular efficiency of viral vectors on the one hand and low immunogenicity and greater flexibility of nonviral vectors on the other hand. The merge of viral and nonviral vector technologies is highlighted as an encouraging strategy for the future; concepts include chemically modified viral vectors ("chemo-viruses") and synthesis of virus-like systems ("synthetic viruses"). Examples for the development of vectors toward artificial synthetic viruses are presented.
引用
收藏
页码:E731 / E742
页数:12
相关论文
共 86 条
[51]   A novel strategy to modify adenovirus tropism and enhance transgene delivery to activated vascular endothelial cells in vitro and in vivo [J].
Ogawara, KI ;
Rots, MG ;
Kok, RJ ;
Moorlag, HE ;
van Loenen, AM ;
Meijer, DKF ;
Haisma, HJ ;
Molema, G .
HUMAN GENE THERAPY, 2004, 15 (05) :433-443
[52]   Melittin enables efficient vesicular escape and enhanced nuclear access of nonviral gene delivery vectors [J].
Ogris, M ;
Carlisle, RC ;
Bettinger, T ;
Seymour, LW .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (50) :47550-47555
[53]   Tumor-targeted gene therapy: strategies for the preparation of ligand-polyethylene glycol-polyethylenimine/DNA complexes [J].
Ogris, M ;
Walker, G ;
Blessing, T ;
Kircheis, R ;
Wolschek, M ;
Wagner, E .
JOURNAL OF CONTROLLED RELEASE, 2003, 91 (1-2) :173-181
[54]   PEGylated DNA/transferrin-PEI complexes:: reduced interaction with blood components, extended circulation in blood and potential for systemic gene delivery [J].
Ogris, M ;
Brunner, S ;
Schüller, S ;
Kircheis, R ;
Wagner, E .
GENE THERAPY, 1999, 6 (04) :595-605
[55]   GENE-TRANSFER INTO HEPATOCYTES USING ASIALOGLYCOPROTEIN RECEPTOR MEDIATED ENDOCYTOSIS OF DNA COMPLEXED WITH AN ARTIFICIAL TETRA-ANTENNARY GALACTOSE LIGAND [J].
PLANK, C ;
ZATLOUKAL, K ;
COTTEN, M ;
MECHTLER, K ;
WAGNER, E .
BIOCONJUGATE CHEMISTRY, 1992, 3 (06) :533-539
[56]   Activation of the complement system by synthetic DNA complexes: A potential barrier for intravenous gene delivery [J].
Plank, C ;
Mechtler, K ;
Szoka, FC ;
Wagner, E .
HUMAN GENE THERAPY, 1996, 7 (12) :1437-1446
[57]  
Portlock JL, 2003, CURR OPIN MOL THER, V5, P376
[58]   A phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme [J].
Rainov, NG .
HUMAN GENE THERAPY, 2000, 11 (17) :2389-2401
[59]   Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer [J].
Raper, SE ;
Chirmule, N ;
Lee, FS ;
Wivel, NA ;
Bagg, A ;
Gao, GP ;
Wilson, JM ;
Batshaw, ML .
MOLECULAR GENETICS AND METABOLISM, 2003, 80 (1-2) :148-158
[60]   Role of clathrin- and caveolae-mediated endocytosis in gene transfer mediated by lipo- and polyplexes [J].
Rejman, J ;
Bragonzi, A ;
Conese, M .
MOLECULAR THERAPY, 2005, 12 (03) :468-474